Reinforcing targeted therapeutics with phenotypic stability factors

Cell Cycle

Volumn 13, Issue 24, 2014, Pages 3818-3822

  Yaswen, Paul ^a  

^a LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

Author keywords

Cancer therapy; Cyclindependent kinase (CDK); Drug resistance; Epithelial mesenchymal transition (EMT); Inflammation; NF kB; Notch; Ovol; TGFb

Indexed keywords

CYCLIN DEPENDENT KINASE 2; REGULATOR PROTEIN; ANTINEOPLASTIC AGENT; CCNE1 PROTEIN, HUMAN; CDK2 PROTEIN, HUMAN; CYCLIN D; CYCLIN E; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NOTCH RECEPTOR; ONCOPROTEIN; TRANSFORMING GROWTH FACTOR BETA;

CANCER CELL; CELL CYCLE; CELL CYCLE PROGRESSION; DEREGULATION; ENZYME ACTIVITY; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; HUMAN; PHENOTYPE; REVIEW; BREAST NEOPLASMS; CANCER STEM CELL; CHEMISTRY; DRUG RESISTANCE; FEMALE; GENETICS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CYCLIN D; CYCLIN E; CYCLIN-DEPENDENT KINASE 2; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; NEOPLASTIC STEM CELLS; NF-KAPPA B; ONCOGENE PROTEINS; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84920607697     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/15384101.2014.985071     Document Type: Review

References (39)

1. Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 2009; 11:R77; PMID:19874578; http://dx.doi.org/10.1186/bcr2419
2. Campos SM, Winer EP. Hormonal therapy in postmenopausal women with breast cancer. Oncology 2003; 64:289-99; PMID:12759523; http://dx.doi.org/ 10.1159/000070284
3. Nahta R, Takahashi T, Ueno NT, Hung M-C, Esteva FJ. P27kip1 down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res 2004; 64:3981-6; PMID:15173011; http://dx.doi.org/ 10.1158/0008-5472.CAN-03-3900
4. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004; 3:1427-38; PMID:15542782
5. Dickson MA, Schwartz GK. Development of cell-cycle inhibitors for cancer therapy. Curr Oncol 2009; 16:36-43; PMID:19370178
6. Ichikawa A, Ando J, Suda K. G1 arrest and expression of cyclin-dependent kinase inhibitors in tamoxifentreated MCF-7 human breast cancer cells. Hum Cell 2008; 21:28-37; PMID:18397472; http://dx.doi.org/ 10.1111/j.1749-0774.2008.00048.x
7. Lane HA, Beuvink I, Motoyama AB, Daly JM, Neve RM, Hynes NE. ErbB2 potentiates breast tumor proliferation through modulation of p27Kip1-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol Cell Biol 2000; 20:3210-23; PMID:10757805; http://dx.doi.org/10.1128/MCB.20. 9.3210-3223.2000
8. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995; 81:323-30; PMID:7736585; http://dx.doi.org/10.1016/0092-8674(95)90385-2
9. Dimri GP. What has senescence got to do with cancer? Cancer Cell 2005; 7:505-12; PMID:15950900; http:// dx.doi.org/10.1016/j.ccr.2005.05.025
10. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic sisease. J Clin Oncol 1999; 17:2639; PMID:10561337
11. Love R. Tamoxifen therapy in primary breast cancer: biology, efficacy, and side effects. J Clin Oncol 1989; 7:803-15; PMID:2654333
12. Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer 2004; 11:643-58; PMID:15613444; http://dx.doi.org/10.1677/erc.1.00776
13. Dean JL, Thangavel C, McClendon AK, Reed CA, Knudsen ES. Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure. Oncogene 2010; 29:4018-32; PMID:20473330; http://dx. doi.org/10.1038/onc.2010.154
14. Abukhdeir AM, Park BH. p21 and p27: roles in carcinogenesis and drug resistance. Exp Rev Mol Med 2008; 10:1-15; PMID:NOT-FOUND; http://dx.doi.org/ 10.1017/S1462399408000744
15. Abukhdeir AM, Vitolo MI, Argani P, De Marzo AM, Karakas B, Konishi H, Gustin JP, Lauring J, Garay JP, Pendleton C, et al. Tamoxifen-stimulated growth of breast cancer due to p21 loss. Proc Natl Acad Sci 2008; 105:288-93; PMID:NOT-FOUND; http://dx.doi. org/10.1073/pnas.0710887105
16. Chu I, Sun J, Arnaout A, Kahn H, Hanna W, Narod S, Sun P, Tan C-K, Hengst L, Slingerland J. p27 phosphorylation by src regulates tnhibition of cyclin ECdk2. Cell 2007; 128:281-94; PMID:17254967; http://dx.doi.org/10.1016/j.cell.2006.11.049
17. Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, et al. Final results of a randomized phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ERC/HER2- advanced breast cancer (PALOMA-1; TRIO-18). Proc Am Assoc Cancer Res 2014; 55:CT101; PMID:NOT-FOUND
18. Fredersdorf S, Burns J, Milne AM, Packham G, Fallis L, Gillett CE, Royds JA, Peston D, Hall PA, Hanby AM, et al. High level expression of p27kip1 and cyclin D1 in some human breast cancer cells: Inverse correlation between the expression of p27kip1 and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci U S A 1997; 94:6380-5; PMID:9177226; http://dx.doi.org/10.1073/ pnas.94.12.6380
19. Mittendorf EA, Liu Y, Tucker SL, McKenzie T, Qiao N, Akli S, Biernacka A, Meijer L, Keyomarsi K, Hunt KK. A novel interaction between HER2/neu and cyclin E in breast cancer. Oncogene 2010; 29:3896-907; PMID:20453888; http://dx.doi.org/10.1038/onc.2010.151
20. Scaltriti M, Eichhorn PJ, Cort-es J, Prudkin L, Aura C, Jim-enez J, Chandarlapaty S, Serra V, Prat A, Ibrahim YH, et al. Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2C breast cancer patients. Proc Natl Acad Sci 2011; 108:3761-6; PMID:NOT-FOUND; http://dx.doi.org/10.1073/ pnas.1014835108
21. Chen J, Wang G. Cyclin E expression and chemotherapeutic sensitivity in breast cancer cells. J Huazhong Univ Sci Technol Med Sci 2006; 26:565-6; PMID:17219969
22. Horiuchi D, Huskey NE, Kusdra L, Wohlbold L, Merrick KA, Zhang C, Creasman KJ, Shokat KM, Fisher RP, Goga A. Chemical-genetic analysis of cyclin dependent kinase 2 function reveals an important role in cellular transformation by multiple oncogenic pathways. Proc Natl Acad Sci U S A 2012; 109:E1019-27; PMID:22474407; http://dx.doi.org/10.1073/ pnas.1111317109
23. Tetsu O, McCormick F. Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 2003; 3:233-45; PMID:12676582; http://dx.doi.org/10.1016/S1535-6108(03)00053-9
24. Bazarov AV, Lee WJ, Bazarov I, Bosire M, Hines WC, Stankovich B, Chicas A, Lowe SW, Yaswen P. The specific role of pRb in p16 (INK4A) -mediated arrest of normal and malignant human breast cells. Cell Cycle 2012; 11:1008-13; PMID:22333593; http://dx.doi. org/10.4161/cc.11.5.19492
25. Centrella M, McCarthy TL, Canalis E. Skeletal tissue and transforming growth factor beta. FASEB J 1988; 2:3066-73; PMID:2903838
26. Singh G, Singh SK, Konig A, Reutlinger K, Nye MD, Adhikary T, Eilers M, Gress TM, Fernandez-Zapico ME, Ellenrieder V. Sequential activation of NFAT and c-Myc transcription factors mediates the TGF-beta switch from a suppressor to a promoter of cancer cell proliferation. J Biol Chem 2010; 285:27241-50; PMID:20516082; http://dx.doi.org/10.1074/jbc. M110.100438
27. Liu F, Korc M. Cdk4/6 inhibition induces epithelialmesenchymal transition and enhances invasiveness in pancreatic cancer cells. Mol Cancer Ther 2012; 11:2138-48; PMID:22869556; http://dx.doi.org/ 10.1158/1535-7163.MCT-12-0562
28. Dontu G, Jackson KW, McNicholas E, Kawamura MJ, Abdallah WM, Wicha MS. Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res 2004; 6:R605-15; PMID:15535842; http://dx.doi.org/10.1186/bcr920
29. Shi W, Harris AL. Notch signaling in breast cancer and tumor angiogenesis: cross-talk and therapeutic potentials. J Mammary Gland Biol Neoplasia 2006; 11:41-52; PMID:16947085; http://dx.doi.org/10.1007/ s10911-006-9011-7
30. Gangopadhyay S, Nandy A, Hor P, Mukhopadhyay A. Breast cancer stem cells: a novel therapeutic target. Clin Breast Cancer 2013; 13:7-15; PMID:23127340; http:// dx.doi.org/10.1016/j.clbc.2012.09.017
31. Andersen P, Uosaki H, Shenje LT, Kwon C.Non-canonical Notch signaling: emerging role and mechanism. Trends Cell Biol 2012; 22:257-65; PMID:22397947; http://dx.doi.org/10.1016/j.tcb.2012.02.003
32. Miele L. Notch signaling. Clin Cancer Res 2006; 12:1074-9; PMID:16489059; http://dx.doi.org/ 10.1158/1078-0432.CCR-05-2570
33. Al-Hussaini H, Subramanyam D, Reedijk M, Sridhar SS. Notch signaling pathway as a therapeutic target in breast cancer. Mol Cancer Ther 2011; 10:9-15; PMID:20971825; http://dx.doi.org/10.1158/1535-7163.MCT-10-0677
34. Smalley M, Piggott L, Clarkson R. Breast cancer stem cells: obstacles to therapy. Cancer Lett 2013; 338:57-62; PMID:22554712; http://dx.doi.org/10.1016/j. canlet.2012.04.023
35. Pandya K, Meeke K, Clementz AG, Rogowski A, Roberts J, Miele L, Albain KS, Osipo C. Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence. Br J Cancer 2011; 105:796-806; PMID:21847123; http://dx.doi.org/ 10.1038/bjc.2011.321
36. Watanabe K, Villarreal-Ponce A, Sun P, Salmans ML, Fallahi M, Andersen B, Dai X. Mammary morphogenesis and regeneration require the inhibition of EMT at terminal end buds by Ovol2 transcriptional repressor. Dev Cell 2014; 29:59-74; PMID:24735879; http://dx. doi.org/10.1016/j.devcel.2014.03.006
37. Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 2009; 139:693-706; PMID:19878981; http://dx.doi. org/10.1016/j.cell.2009.10.014
38. Li L, Zhao F, Lu J, Li T, Yang H, Wu C, Liu Y. Notch-1 signaling promotes the malignant features of human breast cancer through NF-kappaB activation. PLoS One 2014; 9:e95912; PMID:24760075; http://dx.doi. org/10.1371/journal.pone.0095912
39. Gupta SC, Sundaram C, Reuter S, Aggarwal BB. Inhibiting NF-kappaB activation by small molecules as a therapeutic strategy. Biochim Biophys Acta 2010; 1799:775-87; PMID:20493977; http://dx.doi.org/ 10.1016/j.bbagrm.2010.05.004